Eye-movement tests to help detect Alzheimer's disease early
Uses eye-tracking tests and brief memory tasks in adults with Alzheimer's disease and healthy people.
Plain-language title generated from the registry record
Registry title: Development of Eye-movement Based Biomarkers in Alzheimer's Disease
Key facts
- Where
- Montreal and Ville-Marie, CanadaSee the 5 sites
Where in Canada
- Cornelius, a Residence of Groupe MauriceMontreal, CanadaTaking people
- Elogia, a Residence of Groupe MauriceMontreal, CanadaTaking people
- ORA, A residence of Groupe MauriceMontreal, CanadaNot yet recruiting
- The Douglas Research CentreMontreal, CanadaTaking people
- The Montreal Neurological InstituteVille-Marie, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- McGill University
- Trial code
- NCT05176704
- Record updated
- 14 October 2026
- Original description
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.Read full original descriptionShow less
Development of Eye-movement Based Biomarkers in Alzheimer's Disease
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.
This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.
Inclusion: For all participants:; Able to provide informed consent; Aged 18 years or older at the time of enrollment; Able to read in either French or English; Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses; For patients only:; Confirmed diagnosis of AD based on the NIAAA diagnostic criteria of probable AD.
Exclusion: For AD participants:; Diagnosed with one of the following dementia subtypes: Fronto-temporal dementia, Lewy-body dementia, or Creutzfeldt-Jakob disease; Incapacity to provide informed consent or inability to adequately understand the task instructions; For all participants:; Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control; Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia); Diagnosis of macular edema or other pre-existing ocular conditions (e.g., glaucoma, cataracts) that would prevent from performing the eye movement assessments; Unstable medication use: recent (less than one month from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to have an effect on ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. Occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period of an eye movement assessment; Diagnosed with an active substance use disorder; History of stroke may be considered an exclusion criterion, at the discretion of the PI, if judged to potentially affect the cerebral network underlying eye movements and gaze control; Recent traumatic brain injury (within the last 6 months); For healthy controls only:; Evidence or history of significant neurodegenerative disorder affecting brain function (e.g., MS, PD, ALS, Non-AD Dementia).